Profile data is unavailable for this security.
About the company
Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments category include sequencing platforms, microarray scanners, and IVD instruments. Its Kits & Reagents category consists of library preparation kits, sequencing reagents, microarray kits, clinical research products, and IVD products. Its Selection Tools category include Library Prep & Array Kit Selector, Gene Panel & Array Finder, DesignStudio Custom Assay Designer, and other. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It is also a developer of an emerging and highly differentiated single-cell technology.
- Revenue in USD (TTM)4.39bn
- Net income in USD-1.58bn
- Incorporated2000
- Employees10.59k
- LocationIllumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
- Phone+1 (858) 202-4500
- Fax+1 (858) 202-4766
- Websitehttps://www.illumina.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Globus Medical Inc | 2.48bn | 91.51m | 13.26bn | 5.00k | 125.96 | 2.79 | 37.90 | 5.35 | 0.6636 | 0.6636 | 18.08 | 29.94 | 0.4747 | 1.28 | 4.58 | 495,719.20 | 1.75 | 6.90 | 1.99 | 7.45 | 58.14 | 71.73 | 3.69 | 14.05 | 1.64 | -- | 0.0974 | 0.00 | 53.34 | 17.08 | -35.39 | -4.72 | 5.57 | -- |
Revvity Inc | 2.72bn | 258.26m | 13.55bn | 11.50k | 53.15 | 1.72 | 19.73 | 4.98 | 2.09 | 2.06 | 22.06 | 64.88 | 0.2078 | 2.89 | 4.37 | 236,657.00 | 1.97 | 4.76 | 2.15 | 5.39 | 55.44 | 57.19 | 9.49 | 15.34 | 2.97 | 11.96 | 0.2869 | 6.52 | -16.95 | -0.1982 | -64.99 | -5.28 | -2.69 | 0.00 |
Avantor Inc | 6.82bn | 309.60m | 13.71bn | 14.50k | 44.33 | 2.47 | 19.18 | 2.01 | 0.4544 | 0.4544 | 10.01 | 8.16 | 0.532 | 5.56 | 6.09 | 470,331.00 | 2.42 | 2.97 | 2.75 | 3.35 | 33.53 | 33.44 | 4.54 | 5.06 | 1.06 | 3.29 | 0.4698 | 0.00 | -7.26 | 3.51 | -51.52 | -- | 31.17 | -- |
Baxter International Inc | 11.77bn | 225.00m | 16.65bn | 60.00k | 73.82 | 2.12 | 12.70 | 1.41 | 0.442 | 0.214 | 23.10 | 15.42 | 0.4105 | 2.91 | 5.42 | 196,133.30 | 0.8198 | 0.1942 | 1.05 | 0.2333 | 38.43 | 38.20 | 2.00 | 0.3674 | 1.09 | 3.81 | 0.6196 | 1,398.94 | 2.12 | 5.94 | 97.15 | -- | 0.982 | 9.71 |
Align Technology, Inc. | 3.96bn | 441.57m | 16.71bn | 21.61k | 38.16 | 4.24 | 28.71 | 4.22 | 5.87 | 5.87 | 52.63 | 52.76 | 0.6245 | 4.32 | 4.14 | 183,272.50 | 6.96 | 16.34 | 10.39 | 24.14 | 69.98 | 71.72 | 11.15 | 23.16 | 1.14 | -- | 0.00 | 0.00 | 3.42 | 14.45 | 23.09 | 2.15 | -4.46 | -- |
Hologic Inc | 4.03bn | 789.50m | 18.13bn | 6.99k | 23.50 | 3.53 | 16.50 | 4.50 | 3.32 | 3.32 | 16.97 | 22.09 | 0.4406 | 2.72 | 6.57 | -- | 8.63 | 13.12 | 9.84 | 15.20 | 56.25 | 60.82 | 19.59 | 24.75 | 3.03 | 64.45 | 0.3307 | -- | -0.0025 | 3.66 | 73.14 | -- | 4.30 | -- |
Insulet Corp | 1.98bn | 420.90m | 18.70bn | 3.00k | 46.34 | 16.72 | 37.47 | 9.43 | 5.75 | 5.75 | 25.96 | 15.94 | 0.7223 | 1.42 | 6.14 | 661,300.00 | 15.32 | 2.71 | 18.56 | 3.14 | 69.36 | 65.81 | 21.22 | 4.28 | 2.80 | 98.71 | 0.5557 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
Cooper Companies Inc | 3.80bn | 359.30m | 19.73bn | 15.00k | 55.18 | 2.49 | 26.81 | 5.19 | 1.80 | 1.80 | 19.02 | 39.80 | 0.3196 | 1.70 | 5.56 | 253,606.70 | 3.02 | 10.06 | 3.29 | 11.34 | 66.36 | 65.54 | 9.45 | 29.00 | 1.18 | 5.46 | 0.2493 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 0.00 |
Illumina Inc | 4.39bn | -1.58bn | 20.88bn | 10.59k | -- | 9.85 | -- | 4.76 | -10.00 | -10.00 | 27.61 | 13.36 | 0.5441 | 2.66 | 6.17 | 414,542.00 | -19.63 | -6.20 | -23.16 | -7.28 | 63.94 | 66.39 | -36.08 | -15.48 | 1.85 | 38.44 | 0.4834 | -- | -1.75 | 6.21 | 73.64 | -- | -7.91 | -- |
Steris PLC | 5.12bn | 602.62m | 20.95bn | 18.18k | 34.93 | 3.18 | 18.92 | 4.09 | 6.08 | 4.38 | 51.62 | 66.80 | 0.4758 | 3.86 | 5.49 | 281,655.40 | 5.62 | 5.19 | 6.10 | 5.68 | 43.01 | 43.64 | 11.81 | 10.97 | 1.55 | 8.29 | 0.2528 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
Waters Corp | 2.91bn | 622.64m | 21.24bn | 7.90k | 34.14 | 13.25 | 26.07 | 7.31 | 10.48 | 10.48 | 48.89 | 27.00 | 0.645 | 2.20 | 4.47 | 367,740.10 | 13.82 | 19.77 | 16.72 | 25.29 | 59.73 | 58.45 | 21.43 | 23.38 | 1.38 | 10.11 | 0.5325 | 0.00 | -0.5229 | 4.09 | -9.26 | 1.53 | 4.72 | -- |
Zimmer Biomet Holdings Inc | 7.60bn | 1.08bn | 21.75bn | 18.00k | 20.81 | 1.76 | 10.57 | 2.86 | 5.25 | 5.25 | 36.87 | 62.00 | 0.3538 | 0.9136 | 5.38 | 421,972.20 | 5.05 | 2.21 | 5.82 | 2.52 | 71.78 | 71.25 | 14.28 | 7.28 | 0.6987 | 7.52 | 0.3425 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
West Pharmaceutical Services Inc. | 2.88bn | 499.60m | 22.57bn | 10.60k | 46.18 | 8.21 | 35.59 | 7.85 | 6.75 | 6.75 | 38.86 | 37.96 | 0.7743 | 4.50 | 5.51 | 271,358.50 | 13.02 | 15.61 | 15.16 | 18.65 | 34.87 | 38.06 | 16.81 | 18.47 | 2.23 | -- | 0.0695 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
DexCom Inc | 3.95bn | 680.80m | 29.39bn | 9.60k | 45.93 | 14.85 | 32.90 | 7.43 | 1.64 | 1.64 | 9.52 | 5.07 | 0.6107 | 2.76 | 4.42 | 411,875.00 | 10.51 | 8.30 | 14.28 | 10.50 | 62.10 | 65.90 | 17.22 | 14.14 | 2.12 | -- | 0.5579 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Sep 2024 | 15.53m | 9.75% |
BlackRock Fund Advisorsas of 30 Sep 2024 | 13.76m | 8.64% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 5.61m | 3.52% |
Loomis, Sayles & Co. LPas of 30 Sep 2024 | 4.34m | 2.73% |
Baillie Gifford & Co.as of 30 Sep 2024 | 3.62m | 2.27% |
Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 3.54m | 2.23% |
WCM Investment Management LLCas of 30 Sep 2024 | 3.26m | 2.05% |
Geode Capital Management LLCas of 30 Sep 2024 | 2.73m | 1.71% |
GuardCap Asset Management Ltd.as of 30 Sep 2024 | 2.72m | 1.71% |
PRIMECAP Management Co.as of 30 Sep 2024 | 2.52m | 1.58% |